Genomics BioSci & Tech.Ltd Valuation
Is 4195 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4195 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 4195's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 4195's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4195?
Key metric: As 4195 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 4195's PS Ratio? | |
|---|---|
| PS Ratio | 3.1x |
| Sales | NT$417.04m |
| Market Cap | NT$1.29b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.6x |
| Enterprise Value/EBITDA | -26.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 4195's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.3x | ||
4186 Taiwan Advance Bio-Pharmaceutical | 4.1x | n/a | NT$1.4b |
6539 DV Biomed | 0.9x | n/a | NT$1.4b |
1780 Allied Biotech | 2.1x | n/a | NT$1.6b |
6814 Lukas Biomedical | 5.8x | n/a | NT$1.2b |
4195 Genomics BioSci & Tech.Ltd | 3.1x | n/a | NT$1.3b |
Price-To-Sales vs Peers: 4195 is good value based on its Price-To-Sales Ratio (3.1x) compared to the peer average (3.3x).
Price to Sales Ratio vs Industry
How does 4195's PS Ratio compare vs other companies in the TW Biotechs Industry?
| 12 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 21.1x | 28.3% | |
4195 Genomics BioSci & Tech.Ltd | 3.1x | n/a | US$39.44m |
3176 Medigen Biotechnology | 3.4x | n/a | US$147.42m |
4169 TCM Biotech International | 4.2x | n/a | US$108.31m |
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 21.1x | 49.3% | |
4195 Genomics BioSci & Tech.Ltd | 3.1x | n/a | US$39.44m |
Price-To-Sales vs Industry: 4195 is good value based on its Price-To-Sales Ratio (3.1x) compared to the TW Biotechs industry average (20.9x).
Price to Sales Ratio vs Fair Ratio
What is 4195's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4195's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
YungShin Global Holding
NT$15.4b
Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.
3705
NT$57.90
7D
8.2%
1Y
27.1%
Winston Medical Supply
NT$1.6b
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.
6817
NT$88.30
7D
-1.6%
1Y
-13.4%
Cenra
NT$6.0b
Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.
1701
NT$21.15
7D
0%
1Y
-8.8%